STOCK TITAN

Titan Medical to Report Year End 2021 Financial Results on March 24, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) will release its year-end 2021 financial results on March 24, 2022, before market opening. An investor audio webcast will be held at 8:30 a.m. ET to discuss these results and key business highlights. The company is focused on single access robotic-assisted surgery, developing the Enos™ surgical system aimed at enhancing surgical performance. The webcast will be accessible on the company's website and will include speakers Paul Cataford and Stephen Lemieux.

Positive
  • Focused on developing the Enos™ surgical system for robotic single access surgery targeting gynecologic procedures.
Negative
  • None.

TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its year end 2021 financial results prior to market opening on Thursday, March 24, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include Paul Cataford, Interim President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.

A link to the live audio webcast will be made available on the "Investor Relations" section of the Company’s website, www.titanmedicalinc.com. A webcast replay will be archived and accessible on the Company’s website shortly after conclusion of the live audio webcast.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com and follow @TitanMedical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company’s focus on the design and development of surgical technologies for robotic single access surgery; the Enos system providing a surgical experience that imitates real-life movements; and the company’s intention to initially pursue gynecologic surgical indications with the Enos system. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Kristen Galfetti

Vice President

Investor Relations & Corporate Communications

+1-781-869-2553

investors@titanmedicalinc.com

Source: Titan Medical Inc.

FAQ

When will Titan Medical release its 2021 financial results?

Titan Medical is set to release its year-end 2021 financial results on March 24, 2022.

What time will the Titan Medical investor webcast take place?

The investor audio webcast will take place at 8:30 a.m. ET on March 24, 2022.

What is the focus of Titan Medical's Enos™ system?

The Enos™ system is designed to enhance robotic-assisted surgery through a single access point, initially targeting gynecologic surgical indications.

Who will speak at the Titan Medical investor webcast?

Paul Cataford, Interim President and CEO, and Stephen Lemieux, CFO, will speak at the webcast.

TMDI

NASDAQ:TMDI

TMDI Rankings

TMDI Latest News

TMDI Stock Data

16.07M
111.59M
0.08%
4.56%
0.05%
Medical Devices
Healthcare
Link
Canada
Toronto